The Vice Chairman of the 9/11 Commission Calls It Bush's '#1 Priority' And You Can Use It to Increase Your Fortune Seven-Fold By November 30 It's often been said that 'One great speculation is worth a lifetime of prudent investing.' But what happens when that 'great speculation' turns out to be a sure thing? An elite group of investors plans to find out by November 30, 2006. That's the deadline for a blockbuster announcement by the U.S. Department of Health and Human Services that is likely to drive shares of one small-cap pharmaceutical company right into the stratosphere. And could give shareholders an estimated seven-fold return - or more - in the process. Here's how... A relatively unknown biotech company has done something truly extraordinary. It has developed an effective therapy for Acute Radiation Syndrome (ARS), a life-threatening condition that results from exposure to high levels of radiation. The Pentagon wants this drug for U.S. troops in high-risk areas overseas. The U.S. Department of Homeland Security would like to stockpile millions of doses for Americans who live in major metropolitan areas, in case of a terrorist attack. And the Department of Health and Human Services (HHS) has already expressed an interest in purchasing 100,000 doses of this new, patented drug. But that's just the beginning of the story... 'A hundred thousand doses is not nearly enough,' says Lee Hamilton, vice chairman of the 9/11 Commission. 'If you really had a major attack you probably would need much more than that. One estimate we made was that we'd need 10 million doses.' That's right. Ten million doses... Let's do the math. Bought in bulk, the drug can be purchased at approximately $100 a dose. So 10 million doses is a $1 billion order. A billion dollars! Do you realize what an order that size would do to shares of this small company, currently valued at roughly one tenth that amount? The stock will look like something coming off the launch pad at Cape Canaveral. But the federal government may order even more. Perhaps much more. Recent events in the Middle East underscore the urgent need to protect Americans from the unthinkable. As the vice chairman of the 9/11 Commission told CBS News recently, 'What I want to see is the president of the United States and the secretary of Health and Human Services saying 'This is my #1 priority.'' He adds that 'the thing that must be understood is the urgency of the problem. We don't have an unlimited amount of time here.' Now Uncle Sam is moving full speed ahead. An award - which the Department of Health and Human Services recently announced it will make by November 30 - is likely to send shares of this little company blasting higher. That's why I want to give you the details surrounding this exciting development now. This is crucial intelligence. And the clock is ticking. November 30 is just around the corner. Acting on this recommendation now could give you the opportunity to earn up to seven times your money - or more - in just a matter of weeks. This Stock Is Poised for Liftoff Hello. My name is James Livingston. As a leading financial publisher, I've read hundreds of stock stories in my career. But never before in my life have I heard a more exciting or timely investment idea - with more upside potential - than this one. Within a matter of days, I fully expect this pharmaceutical firm to get an order from the U.S. government worth up to 10 times the firm's total stock market value. This is extraordinary news, of course. And it means a select group of investors stands to get very rich, very quickly. And you now have an opportunity to join them. What the Pentagon Wants, the Pentagon Gets Let me start at the beginning... In the summer of 2001, the U.S. military visited this small pharmaceutical company in San Diego to speak with them about their new drug to treat radiation sickness. A potential radiation attack is a constant threat for U.S. troops, of course. And the Pentagon told the company 'You know we've been testing your drug and we've been looking for a drug like this for 40 years.' Two weeks after 9/11, they visited the company again and said, 'we'd like to develop this now, not only for troops but for civilians.' The drug had not yet received FDA approval. But the Pentagon had already been testing it on mice, dogs and monkeys, where it stopped the lethal bleeding and infections caused by radiation exposure. In short, it worked. The Pentagon decided the drug was in a class by itself and stated in a letter to CBS News that the drug 'seems to be the most effective, least toxic and most comprehensive in its effects.' And it has other major advantages. The Pentagon's chief radiologist says, 'one of the most desirable features of [this drug] is that it could be self-administered without physician supervision in a disaster scenario.' The drug could be in a cartridge with a needle that you could inject in your thigh. This is crucial because in the event of a radiation disaster in a major American city, like New York or Washington, the overwhelming majority of victims would not have access to medical personnel. That's why the government needs to stockpile the drug. Investors looked at the numbers. And realized they were staggering. The potential market here is absolutely gigantic. That potential became a reality when President George Bush made an important proposal in 2003. In his State of the Union address, President Bush said, 'I ask you tonight to add to our future security with a major research and production effort to guard our people against bio-terrorism, called Project Bioshield.' Within 10 months, Bush signed his plan into law. Project Bioshield provided $5.7 billion in funding to protect Americans against a chemical, biological, radiological or nuclear attack. The program gives drug companies a powerful incentive to develop new drugs. For the first time, there would be a guaranteed market for drugs that tested successfully. And this was just the assurance this San Diego company had been waiting for. Following Bush's proposal, traders and investors pounced on shares of the biotech company, driving the price up more than seven-fold from where it was less than a year earlier. 'The investors looked at our data, and knew we had a very encouraging drug,' says the company's vice president. 'Nobody argued the science. It was very effective in non-human primates. So you put two and two together. You invest in the company.' In life, however, timing is everything. These investors weren't wrong. But - as it turned out - they were too early. Uncle Sam Drops the Ball... Over the next three years, this biotech firm banked on the credibility of the U.S. government and spent more than $100 million, with the reasonable expectation that the government would buy millions of doses. But then - like a bolt out of the blue - the Department of Health & Human Services surprised everyone by announcing that it would purchase whichever radiation drug was most effective, but only 100,000 doses. Investors - and company executives - were shocked. Nobody expected the order to be that small. How can you safeguard hundreds of millions of Americans with 100,000 doses? Needless to say, the stock retreated. And shareholders, Pentagon officials and many of our elected representatives got very, very angry. After all, the security threat is genuine. The drug works. And it must be stockpiled to effectively stem the threat. Lee Hamilton, vice chairman of the 9/11 Commission, fumed that the HHS proposal for a mere 100,000 doses was totally ridiculous. Who made the decision? It turns out it was Stewart Simonson, the man who oversees Project Bioshield. He is a political appointee who used to be a lawyer for Amtrak. And many Republicans and Democrats agree he is unqualified for the position. 'Secretary Simonson just appears to be over his head on this particular issue,' says Rep. Tom Davis, a Virginia Republican who also chairs the committee that oversees Project Bioshield. Rep. Davis is not just flapping his gums. Comparing him to Michael Brown, the former head of FEMA who botched the recovery effort in New Orleans after Hurricane Katrina, Davis has taken the unusual step of calling for Simonson's removal from office. So far, it hasn't happened. But the truth is it doesn't need to now. Whether it was calls for Simonson's resignation or just the triumph of common sense, Uncle Sam has finally gotten the message. The Big News Should Come No Later Than November 30 In a letter dated June 23, 2006 the Department of Health and Human Services notified the San Diego biotech firm that it has formally begun the process for a potential procurement. And they estimate the award will come by November 30, 2006. A major announcement would send this stock soaring, of course. That's why savvy investors should snap up shares of this company now. Why? Because while the deadline for the award is November 30, it could come even sooner, sending shares of this company rocketing higher immediately. Perhaps even tomorrow. Early investors could easily see history repeating itself - with the stock rising seven-fold or more... again. Only this time it will be going up on the news... not just the rumor. That's why you need to own this stock now. Today. And here's the part I found really surprising: This stock should be a fabulous investment, even in the unlikely event that the company DOESN'T get an order for millions of doses of its radiation drug. This Small Fish Is About to Get Gobbled Up By a Large Fish Our favorite biotech company isn't riding on its anti-radiation drug alone. It also is successfully profiling drug candidates in a number of therapeutic areas, including metabolic and autoimmune disorders, pulmonary diseases and oncology. Most of the company's research centers on dehydroepidandrosterone (DHEA), a hormone with many biological properties associated with health and healing. Since the Nobel prize-winning discovery of this 'mother hormone' in the 1930's, many researchers have come to believe it is a biomarker of longevity. And this biotech company - impressed by its potential - has set up collaborations with other companies and acquired exclusive rights to several issued patents. That means the molecules the company is developing could eventually be developed into a whole pipeline full of effective new drugs. More importantly, that means this company is on virtually every big drug company's radar screen as a prime takeover candidate. Especially given the exciting news due by November 30. The Anatomy of a Takeover Candidate Here's what I love about this investment opportunity: Investors stand to make a ton of money from a pending announcement by the Department of Health and Human Services. But they also stand to hit the jackpot if the company suddenly receives an unexpected takeover bid. Either before or AFTER the announcement. In other word, heads - you win. Tails - you win. That's what happens with a lot of ideas I get - as I did this one - from Takeover Specialist Louis Bass and his team of researchers. Louis has a unique system for spotting takeover candidates BEFORE an announcement is made. And now he's sharing his secrets - including this hot new biotech play - with a select group of investors. Let me tell you why. A Strategy That Leads to 'Exceptional Returns' The 'Smart Money' has known for years that the biggest scores are often made by investing in companies that are prime acquisition targets. After all, what other news can make a stock soar 50%, 75% or 100% in value... instantly? Bloomberg News refers to the takeover game as 'the most lucrative money-maker on Wall Street.' And there is plenty of research to back up this view. Recently, for instance: AT&T Wireless shares soared more than 98% in the month it was rumored several competing wireless providers had the company in their sights... HPSC, Inc. shares recently popped 57% in a single day when General Electric announced it was buying the company... Lattitude Communications, Inc. rose 39% over a three-week period upon news of Cisco Systems' interest... When Novartis began making noise that it was interested in a takeover of Aventis, Aventis shares rose 18% in 2 weeks... NetScreen very recently jumped 42% in the three days following Juniper Networks' announcement that it had agreed to buy out the Internet software company... Wouldn't it be great if you held these stocks before the takeover bid was announced? In fact, you can. Leading companies - those that have benefited most from the recent recovery - suddenly find themselves flush with cash. And rather than pay dividends to shareholders, they are opting to further bolster growth by acquiring rival companies that are still trading at bargain basement prices, especially after the recent correction. And the important thing is the gains often come in a matter of days. Sometimes in as little as a few hours. Just imagine the kind of impact such a strategy could have on your portfolio... Mergers & Acquisitions Hit Record Levels Each year, literally thousands of takeovers are announced in the U.S. And the number is growing. For instance, in 2004 there were 8,550. In 2005 there were 9,045. With so many opportunities, investing in only a handful of these deals could easily turn a mere $10,000 into a $4.4 million jackpot. Let me show you how: Say you started with $10,000 and invested it in one takeover stock. You held onto the position until a deal was announced (again, remember it's often as quick as a couple days, even hours). You then take your profits and roll the proceeds into the next takeover stock. 'Being on the right side of a merger deal can mean a quick profit.' ~ USA Today Do this five times and your original $10,000 would be worth more than $75,000. Do this only 10 times and you'd be sitting on more than $575,000. After just 15 successful trades, you'd be sitting on a $4.4 million jackpot. Remember, this is just based on the recent averages. Often times, the gains for individual takeovers are much, much higher. Just consider these recent takeover gains... 71% in Concord Communications, Inc. 86% in Retek 154% in PracticeWorks, Inc. 108% in Moore Medical 250% in Owosso Corporation With such unmatched profit potential, it's no wonder one analyst from StreetAuthority.com notes, 'merger and acquisition deals can be a bonanza for those who invest in the target company's stock.' Fortune magazine confirms that 'there's big money to be made if you can identify the next targets and buy in before everyone else does.' The Next TakeOver Candidates Are... "The renewed interest in pursuing mergers and acquisitions came amid signs of an improving economy and a rising U.S. stock market. After two years of repairing balance sheets, companies began thinking about growth via acquisition. Also, financing markets opened up, making it easier and cheaper for buys to fund deals." When you own companies 'ripe for the picking' in today's hot takeover market... stocks in your portfolio start popping like Jiffy Pop popcorn on a hot stove! And the reason is that traders can't help themselves when news of a takeover breaks... Imagine you're working at a trading desk of a typical Wall Street firm. The usual stuff is going on. A good earnings release here, a disappointment there. Bernanke is going to address Congress at 3 o'clock. Revised GDP figures come out after the market closes. And so on. Suddenly a runner bursts into the room. 'Comcast has just made a bid for Disney!' Every trader in the room pounces on his computer immediately. The news is just breaking. Disney shares are rocketing upward. Everyone's pulse is pounding. Now the orders come pouring in. 'Buy me 50,000 shares!' 'Buy 200,000 shares!' 'Where's the market now? What? Okay, buy it. Just get me in on this deal NOW!' In fact, very few market events can drive a stock higher, faster than an unexpected takeover bid. That's why owning takeover targets before the takeover news hits the wire can be so lucrative - and can easily put hundreds of thousands of dollars in stock market profits in your hands in the coming weeks. But you need to know which companies are the most likely takeover targets. That's why I'm so excited to introduce to you The TakeOver Trader, researched and edited by Louis Bass. The TakeOver Trader is an elite trading newsletter with just one mission: to put the hottest and most successful takeover targets in your hands before the rest of the investment world knows about them. And the takeover market has never looked better than it does now. Why? Because rather than distribute profits by way of dividends, smart companies will look to strengthen their position in the marketplace by snapping up well-priced industry rivals that have the kind of valuable assets they're looking for: customers, market share, technology, patents, and so on. Finding the most likely takeover candidates, however, takes lots of time, dedication and hard work. It involves hundreds of hours of research, analysis and hardheaded due diligence. It takes contacts with dozens of business leaders, Wall Street analysts, well-connected bloggers and, frankly, even the occasional rumormonger. Just ask Takeover Specialist Louis Bass. Take Advantage of an Exclusive Wall Street Connection With a career already behind him at one of the world's top investment banks - and an MBA from prestigious Rollins College - Louis has spent the better part of his career analyzing what makes a company a compelling takeover candidate. In fact, it's fair to say it's his consuming passion. He loves the challenge of targeting shares in a company just weeks (or days) before a takeover bid is launched... and then watching the stock price soar when an announcement is made. Over the years, he's developed a proprietary system that identifies target companies just prior to a takeover. And his technique allows him to 'key in' on the most potent takeover targets just as they're emerging. He calls it the 'Q-U-I-C-K' strategy. And now you could use it to bag some of the biggest profits U.S. investors will see in the months just ahead. In fact, he's so good at it that I'm prepared to make you a highly unusual offer: If you don't have the opportunity to at least double your money in the next year with this biotech stock I've been telling you about - and Lou's other top recommendations - my publishing company will pay you. That's right. I'm so confident that this strategy will deliver market-trouncing gains that if you don't have the opportunity to at least double your money in the next year, I will open up my pocketbook and pay for an entire second year of The TakeOver Trader. I truly believe that it could be the fastest and most prudent way to increase your fortune seven-fold ... or more. Over the past few years, Louis has helped deliver one blockbuster gain after another to subscribers of The TakeOver Trader. Those gains include 86% in less than three weeks in Monster Worldwide... 104% in three weeks in Atherogenics, Inc... 179% in less than one month in MBNA... 200% in Western Gas Resources in just two months... 332% in seven weeks in Netflix... Even 396% in just over three months in Murphy Oil. Bear in mind, not all of these companies got bought out. But Louis was able to deliver the goods just because of their takeover potential. In short, his TakeOver Trader has been a win-generating machine, delivering no fewer than 28 double-digit and 19 triple-digit winners overall. Here's exactly how he does it... and you can, too. The Q-U-I-C-K Path to Verified Gains of 396%... 592%... even 1,223% Before you join The TakeOver Trader, I'd like you understand exactly how Louis' proprietary Q.U.I.C.K. strategy works. It begins with... Quiet whispers... Nothing can send a stock soaring higher or faster than rumor and speculation. But long before takeover rumors reach The Wall Street Journal, CNBC, Investor's Business Daily or Barron's, there have been weeks of 'whispers' among the industry insiders, key players in the powerful investment banking industry, even hedge fund managers. All it takes is a passing comment by an assistant... a slip of the tongue by a key player... or for a private memo to 'accidentally' fall in the wrong hands. Fortunately, Louis spends the majority of his time working, dining and socializing with important players in business, finance, publishing, mergers and acquisitions, and investment banking. If anyone's in position to catch wind of these 'whispers' it's Mr. Bass and his long list of contacts. Unusual spikes in trading volume... Once a company is a takeover target, people 'in the know' are likely to start buying it. That's why trading volume is such a powerful takeover clue. One of The TakeOver Trader's positions - Monster Worldwide - is a classic example. Louis' research and sources convinced him that the burgeoning online employment industry was due for some consolidation. Not long after he recommended the stock, Monster's trading volume spiked to more than double the daily average... fueling speculation that another deal was in the offing. Monster shares soared on the rumor. By the time we closed out of those positions we saw gains of 35% on the stock, and 86% and 150% on our options recommendations. Who knows if and when a deal will go down? But here the important point: There's often plenty of money to be made just on the rumor! Intrinsic Value... A company must have two things going for it to be taken seriously as a takeover candidate. It has to be incredibly cheap relative to its peers... and it must offer something special: market share, brand-name products, patents, long-term customers, and so on. Abbott Laboratories' recent takeover of TheraSense was a classic case of a smaller company having something an industry giant wanted badly. TheraSense owned patents to the FreeStyle blood glucose monitoring system - a popular product among diabetics. Given Abbott's recent interest in other companies with proprietary products in this field - and the fact that TheraSense's stock price was just coming off all-time lows - this was a takeover just waiting to happen. Had you known, you could have bought TheraSense for just over $11 a share - and cashed out at more than $26 a share following Abbott's takeover... Consolidation Trends... Ever since the early 1900s, when the burgeoning auto industry was reduced from more than 100 companies to a handful, industry consolidation has been a constant in every sector of the marketplace. It happened most recently in the computer, technology and Internet sectors... and it's happening in many sectors today, including media, telecommunications, banking and, of course, biotechnology. In May, for example, Wachovia bought Golden West Financial. A couple months earlier, Capital One snatched up North Fork Bancorp and Hibernia. And the CEO of JP Morgan Chase recently confessed that the company was on the hunt again (resuming a ravenous appetite for takeovers after completing 20 mergers in just 15 years). But the banking sector is merely one example. The truth is that there have never been so many companies in so many sectors that have been so ripe for takeovers. And these announcements can make you many thousands of dollars - instantly - in the weeks ahead. Despite the recent bull market, many companies are trading near historic lows. Yet, they have technologies, customers and market share that rival companies want - badly. And the generous premium they're willing to pay to get them can result in hefty profits for alert 'takeover' traders. Keen 'Insider' Interest... Insiders can reveal a lot about a company's immediate future. Although it's illegal for insiders to trade shares solely on insider or non-public information, a company insider can always justify pre-takeover stock purchases by citing other factors. That's why - when all the other Q-U-I-C-K signals point to a takeover in the offing - it's important to look closely at what company insiders have been doing over the past 18 months or so. If there's more buying than usual, you might assume insiders have reason to believe a takeover is possible. In fact, of the 36 companies The TakeOver Trader has been tracking lately, insiders were extra busy in half of them. It's a nice 'head's up' when the other signals are also blinking 'go.' Make Money Even When You're Wrong! The beauty of the Q.U.I.C.K. strategy is that you don't even have to be right about a merger every time to make truckloads of money. Even the picks that aren't eventually bought out often deliver handsome profits. It's not hard to see why. Lou's proprietary screens select companies that are significantly undervalued. It's one of the reasons other companies are interested in acquiring them, of course. However, it also ensures you have a high margin of safety and an excellent chance of a rebound - on value alone! So subscribers to The TakeOver Trader have made money when Lou's picks are suddenly bought out... as well as on rumors of an expected takeover. But also just from sudden appreciation when the market realizes that a company is simply far too cheap. Just consider the gains subscribers had the opportunity to lock in on prime takeover candidates that never received a formal offer. Lou's Monster Worldwide play soared more than 150% in the months after InterActive Corp. (the owners of Expedia, Hotwire and Hotels.com) indicated they were looking for a cheap way to bolster their online dominance. optionsXpress options jumped 1,223% in just 14 weeks, when the rumor mill suggested one of the big exchanges was sizing up the company's increasingly profitable options trading platform. Shares of Celgene rocketed 74% higher as positive clinical results for its potential blockbuster drug Revlimid spurned speculation that the big pharma companies were poised to start a bidding war. Tom Online jumped 44% when domestic Internet behemoths announced plans to expand into the rapidly expanding Chinese market. Internet Security Systems rose more than 55% after speculation that Cisco Systems, among others, might have the company in its sights... Shares of Atherogenics soared 64% in a single day... and more than 104% - from $16.11 to $33 - in less than three months, as positive test results from the company's potential blockbuster drug moved Atherogenics rapidly up the biotechnology potential-acquisition list. Your New Guru in Gains Rest assured, finding takeover candidates before an announcement is made is hard work. Fortunately, you don't have to comb through spreadsheets and databases. You don't need to align yourself with business executives and industry insiders. You don't have to spend hours sorting out fact from fiction in Wall Street's ongoing rumor mill. Takeover Specialist Louis Bass does it all for you... He's made a systematic study of the qualities that takeover candidates generally exhibit BEFORE they are bought out... and his Q-U-I-C-K strategy is designed so that no company with takeover potential escapes our tightly strung net. He has top-notch contacts at some of the biggest investment banks on Wall Street. In short, Louis Bass is one of the smartest, most insightful analysts working in investment publishing today. And now, he's willing to teach you. You'll hear all the quiet whispers. You'll know who's eyeing whom. And you'll have all the research to back it up, right at your fingertips. All you have to do is wait by your computer (or fax machine) for the next hot takeover target to arrive... decide if you want to act on it... contact your broker... and wait to hit the jackpot. If TakeOver Profits Appeal to You... In a moment, I'm going to show what you need to do to get in on the takeover mania that's already occurring in today's markets. What's more, I'll tell you how you can try The TakeOver Trader at a very specially negotiated price - with an unheard-of guarantee. Yes, the biotech firm that is just days away from a major contract is likely to be the first addition to your portfolio. But there are plenty of other great takeover candidates you'll likely be hearing about in the weeks ahead - companies that Lou's Q.U.I.C.K. strategy says are ripe for a buyout any day now... Cashing In On the Red-Hot Banking Sector There's no denying that consolidation is in high gear for the banking industry. And two companies are about to 'pop' on Lou's takeover radar. One company has spent the better part of five years gobbling up other banks, but that's about to change. After an aggressive and successful takeover strategy, this company now enjoys a solid foothold in the highly desirable New England market. With profits steadily climbing, the value of this company to the larger national banks is heating up. A bid from a larger bank could come virtually any day now. But that's not the only banking target. Large national banks are clawing to get hold of market share in highly profitable states such as Florida, Texas and Alabama. The second banking target provides a quick, profitable and extensive entry into the Southern markets. If the premiums paid in six recent banking deals are any indication, this stock is likely to go at an enormous premium. Get it while it's still cheap... Hit the Gas With This Takeover Candidate, Too Commodities are another sector ripe for consolidation. And the mergers and acquisitions are booming here, too. For example, in the past two years, there were six takeovers announced among natural gas producers with operations in the Rocky Mountains. Each of the stocks skyrocketed on the news. Why? Because natural gas production in the traditional regions (namely, the Gulf of Mexico) is declining. However, natural gas production in the Rockies is booming. For any producers looking to expand, it's the most promising frontier. However, only one major producer remains. Given the history of consolidation, this is a no-brainer for anyone seeking hot new takeovers. The company controls more than 300 square miles of prime Wyoming gas fields. And it boasts top-notch fundamentals with triple-digit earnings growth, a 71% increase in production and a 42% uptick in proven reserves. Tack on the company's offshore China drilling sites and it's easy to see why suitors are salivating. You'll want to add this stock to your portfolio immediately - because a deal could be announced virtually any day now. New Takeovers Are Announced Every Day! These are just a few of what will surely be a long string of takeover candidates as 'takeover mania' continues in the market. In the weeks ahead, you'll be hearing about the companies the insiders (including hedge fund managers and powerful investment bankers) are talking about - and whose fundamentals point to being prime takeover candidates. I invite you to use this information to increase your net worth seven-fold or more. As a TakeOver Trader subscriber, you'll see all the best takeover targets - including our favorite biotech stock - and you'll be amazed at how fast the profits can grow when a company falls into the crosshairs of another company. Just recently, we've seen companies popping 31%, 58%, 93%, 102%, even 250% higher in a matter of days, as news of a potential takeover hits the mainstream market. As a TakeOver Trader subscriber, you can be in long before most investors - watching as the stock rises on the rumor... and explodes for even bigger profits the day the takeover news is announced. It works like this: The instant a takeover rumor surfaces, The TakeOver Trader team is on the case... gathering the facts... applying the Q-U-I-C-K strategy test... and getting the 'insider's angle' from our deep-rooted contacts within the investment banking community as well as the industry in question. Once everything checks out, an instant e-mail (or fax) alert goes out to you with precise instructions on what action to take: what stock to buy... how much you should pay... the gains you can expect to make... and when you can expect the deal to go down. Plays for Speculators, Too Each recommendation will include a 'straight' stock play, where you buy the stock... hold it until it pops... and collect the jackpot when we recommend a sell. If there's an attractive option play available, we'll offer it as a more speculative position, in addition to the straight stock play. If the takeover target moves before the option expires, it's possible to increase your jackpot winnings by four, five - even 10 times the profits you could earn buying the stock outright. Be Prepared to Act Quickly Regardless of whether you buy the stock, the option, or both - it's imperative that you act immediately. You never know when a takeover deal will go down. It could be weeks. It could be tomorrow. But when it does, you want to be in the know. And that requires action on your part. The same holds true now. For a very limited time, we've negotiated a special discount for you. But before you decide whether or not The TakeOver Trader is for you, please understand two things: First, as you might have gathered, The TakeOver Trader is a premium service for serious investors looking to gather investment intelligence about a very specific area of the market. Hiring a hedge fund manager that uses the same strategy could easily cost you upwards of $25,000 a year or more, making the cost of $1,990 to get into The TakeOver Trader (which offers the same kind of high-level investment recommendations employed by the most successful hedge funds) an absolute bargain. But because you are an Investment U reader, you can now receive an entire year of The TakeOver Trader for half off, or just $995. That's a full $995 off the price you would normally pay for the service. The second thing I'm obliged to tell you is that spots are limited. Why? Because some of the most lucrative takeover targets involve smaller-cap companies - companies that can soar 100%, 200%, 300% in a day when named in takeover talks. So we have to be careful. Too many investors trying to get into one of these plays could spoil the opportunity. However, I want to give you even further assurance. Double Your Money or We'll Pay You We're so confident that The TakeOver Trader has the ability to increase your net worth several-fold that if you don't get the chance to at least double your money in the next year, we will open up our pocketbooks and pay for an entire second year of this elite service for you, free of charge. Instead of just reading all the merger headlines week-in and week-out, you'll be in on the deals... before they happen. But I urge you to act now. '2006 May Well Be the Best Year Ever For Mergers and Acquisitions.' - Paul Taubman, Global Head of M&A at Morgan Stanley Takeover mania is heating up. Bloomberg News just reported that '2006 may well be the best year ever for mergers and acquisitions.' Research from Thomson Financial confirms that $333.7 billion in deals have already been announced this year (the third-best start to a year ever). The good news, though - there's at least $700 billion more to come. Even Lehman Brothers (one of the top advisors to companies considering takeover offers) predicts merger and acquisition activity will increase by at least 20%, to reach record levels not seen since 2000. "During the next six years, we could see some of the biggest mergers in history." Please don't miss out on this extraordinary opportunity. Hundreds of deals will be unfolding in the weeks ahead. But these returns will only be available to a select few. We expect there will be a lot of competition for the limited number of spaces. (We will, however, maintain an active waiting list.) That's why it's so important for us to hear from you today. Simply click the Subscribe Now link at the bottom of this letter to accept this special members-only discount. Or feel free to call our Member Services Department at 1-888-570-9830 and we'll process your order. It may well be the most successful financial alliance you ever make. Sincerely, James Livingston Publisher, Monument Street Publishing October 16, 2006 P.S. Bear in mind, the biotech takeover I've outlined above could alone be worth many times the cost of your one-year subscription to The TakeOver Trader. Within a matter of days, investors are likely to be stampeding into the stock. Activate your subscription today! P.P.S. Please be aware that the special price we've negotiated for you - as well as the second year guarantee - could be withdrawn at any time. Please act now.